Cefpodoxime


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Resp tract infections; UTI 100-200 mg 12 hrly. Skin and soft tissue infections 200-400 mg 12 hrly. Uncomplicated gonorrhoea 200 mg as a single dose.
Dosage Details
Oral
Acute otitis media
Child: ≥15 days 4 mg/kg 12 hrly. Max: 200 mg daily.

Oral
Skin and soft tissue infections
Adult: 200-400 mg 12 hrly.
Child: ≥15 days 4 mg/kg 12 hrly. Max: 200 mg daily.

Oral
Respiratory tract infections, Urinary tract infections
Adult: 100-200 mg 12 hrly.
Child: ≥15 days 4 mg/kg 12 hrly. Max: 200 mg daily.

Oral
Uncomplicated gonorrhoea
Adult: 200 mg as a single dose.
Renal Impairment
Patient on haemodialysis: Dose should be given after each dialysis session.
CrCl (mL/min)
Dosage
<10 Increase dosing intervals to 48 hrly.
10-39 Increase dosing intervals to 24 hrly.
Administration
Should be taken with food.
Reconstitution
Reconstitute powd for oral susp at the time of dispensing by adding the amount of water specified on the container to provide a susp containing 50 mg or 100 mg per 5 mL. Add water in 2 equal parts and shake the bottle vigorously after each addition.
Contraindications
Hypersensitivity to cefpodoxime or other cephalosporins.
Special Precautions
Patient w/ history of penicillin allergy. Renal impairment. Childn. Pregnancy and lactation.
Adverse Reactions
Diarrhoea, nausea, abdominal pain, vomiting, diaper and skin rash, headache, vag infection. Anxiety, chest pain, cough, decreased appetite, dizziness, dysgeusia, epistaxis, eye pruritus, fatigue, fever, flatulence, flushing, fungal skin infection, hypotension, insomnia, malaise, nightmares, pruritus, purpuric nephritis, tinnitus, weakness, xerostomia, vulvovaginal candidiasis.
Potentially Fatal: Anaphylaxis, Clostridium difficile-associated diarrhoea and colitis.
MonitoringParameters
Monitor renal function; observe for signs and symptoms of anaphylaxis during 1st dose.
Overdosage
Symptoms: Nausea, vomiting, epigastric distress and diarrhoea. Management: Haemodialysis or peritoneal dialysis may be useful in the event of a serious toxic reaction particularly if renal function is compromised.
Drug Interactions
Antacids or H2-blockers may decrease the absorption of cefpodoxime. Reduced renal excretion w/ probenecid.
Food Interaction
Cefpodoxime levels may be increased w/ food.
Lab Interference
Urinary glucose test using cupric sulfate (e.g. Benedict's or Fehling's tests soln, Clinitest®) may produce false-positive result. May induce a positive direct Coombs' test; false-positive serum or urine creatinine w/ Jaffe' reaction.
Action
Description: Cefpodoxime binds to 1 or more of the penicillin-binding proteins (PBPs) which inhibit the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
Pharmacokinetics:
Absorption: Rapid and well absorbed from the GI tract (approx 50%). Decreased absorption in low gastric acidity conditions. Food may increase bioavailability. Bioavailability: Approx 50%. Time to peak plasma concentration: Approx 2-3 hr.
Distribution: Reaches bile, resp and genito-urinary tract (therapeutic concentrations); enters breast milk (low concentrations). Plasma protein binding: Approx 20-30%.
Metabolism: De-esterified to cefpodoxime in the intestinal lumen.
Excretion: Via urine (80% as unchanged drug). Plasma half-life: Approx 2-3 hr.
Chemical Structure

Click on icon to see table/diagram/image
Storage
Store between 20-25°C. Reconstituted powd: Store between 2-8°C.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Cefpodoxime from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in